Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2350]

Prof Maria Ribal discusses how effective dissemination is key to PIONEER’s long...

Prof Maria Ribal - Chairperson, EAU Guidelines Dissemination Committee

Prof Maria Ribal discusses how effective dissemination is key to PIONEER’s long-term success ( Prof Maria Ribal - Chairperson, EAU Guidelines Dissemination Committee )

Dr Mieke Van Hemelrijck explains the importance of define core outcome sets for...

Dr Mieke Van Hemelrijck - Kings College London, Translational Oncology &...

Dr Mieke Van Hemelrijck explains the importance of define core outcome sets for prostate cancer ( Dr Mieke Van Hemelrijck - Kings College London, Translational Oncology & Urology Research (TOUR) )

PIONEER research associates from both academic and industry discuss their...

Claudio Sartini, Katharina Beyer, Eleni Vradi, Dr Lisa Morris, Dr Kostas...

PIONEER research associates from both academic and industry discuss their experience of working together ( Claudio Sartini, Katharina Beyer, Eleni Vradi, Dr Lisa Morris, Dr Kostas Dimitropoulos, Dr Peter-Paul Willemse )

Dr Thomas Abbott, EFPIA co-lead for PIONEER, discusses data sources and access...

Dr Thomas Abbott - Head, Real World Evidence at Astellas Pharmaceuticals

Dr Thomas Abbott, EFPIA co-lead for PIONEER, discusses data sources and access to data ( Dr Thomas Abbott - Head, Real World Evidence at Astellas Pharmaceuticals )

Dr Zsuzsanna Devecseri, EFPIA co-lead for PIONEER, discusses prostate cancer...

Dr Zsuzsanna Devecseri - Head, Global Oncology Medical, Sanofi

Dr Zsuzsanna Devecseri, EFPIA co-lead for PIONEER, discusses prostate cancer outcomes ( Dr Zsuzsanna Devecseri - Head, Global Oncology Medical, Sanofi )

Second-line and beyond in mCRC: Optimising the benefit and reducing the risk

Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA

Second-line and beyond in mCRC: Optimising the benefit and reducing the risk ( Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA )

Controversies in the management of prostate cancer

Prof Mach Roach III - University of California, San Francisco, USA

Controversies in the management of prostate cancer ( Prof Mach Roach III - University of California, San Francisco, USA )

Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus...

Prof John Marshall - Georgetown University Hospital, Washington D.C., USA

Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus 6 months ( Prof John Marshall - Georgetown University Hospital, Washington D.C., USA )

Rectal cancers: Positioning of watchful waiting and minimally invasive...

Prof Henk Wegstapel - Canterbury Christ Church University, Canterbury, UK

Rectal cancers: Positioning of watchful waiting and minimally invasive procedures ( Prof Henk Wegstapel - Canterbury Christ Church University, Canterbury, UK )

Using genetic testing to tailor chemotherapy

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Using genetic testing to tailor chemotherapy ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Highlights from IGILUC 2019

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt

Highlights from IGILUC 2019 ( Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt )

ALK-positive NSCLC: Treatments and latest developments

Prof Tony Mok - Chinese University of Hong Kong, Hong Kong

ALK-positive NSCLC: Treatments and latest developments ( Prof Tony Mok - Chinese University of Hong Kong, Hong Kong )

More from ecancer